Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07759154 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Trial sites expanded: 0 → 16 locations · Start date changed from estimate of Aug 20, 2026 to Sep 1, 2026v2 Show 2 more changesShow less
    • Trial sites expanded: 0 → 16 locations
    • Start date changed from estimate of Aug 20, 2026 to Sep 1, 2026
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Astex Pharmaceuticals
103 trials monitored
See 3 trials at risk
ADHD
387 trials monitored
See 23 trials at risk
The primary purpose of this study is to evaluate the efficacy of centanafadine once daily (QD) extended-release (XR) capsules in adults with attention-deficit/hyperactivity disorder (ADHD) and emotional dysregulation (ED).
Trial Details
NCT Number NCT07759154
Lead Sponsor Otsuka Pharmaceutical Development & Commercialization, Inc.
Conditions Attention-deficit/Hyperactivity Disorder, Emotional Dysregulation
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov